Former AstraZeneca exec takes charge at Enhanc3D Genomics
Enhanc3D is developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification. As COO and interim CEO, Dr Jones has played a leading role in transitioning the Company's 3D genomics platform from development to practical application in R&D.
With over a decade of senior leadership experience in oncology research, Dr Jones brings expertise in all phases of drug development, from target validation to clinical development, driving operational change to advance disease diagnosis and treatments.
Prior to joining Enhanc3D Genomics as COO in November 2023, she held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R & D. She was also previously Head of Combination Therapies at Cancer Research UK.
Dr Chris Torrance, Chairman of the Board of Directors, Enhanc3D Genomics, said: “We're thrilled to officially appoint Hazel as CEO. Her guidance as COO and interim CEO has been instrumental in driving Enhanc3D Genomics’ global operations, forming new connections and developing existing strategic partnerships. On behalf of the Board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the Company.”
Enhanc3D Genomics has established a genome-wide 3D-genome mapping technology, GenLink3D™, which provides profound insights into long-distance gene regulation and disease pathways, demystifying the non-coding genome.
GenLink3D profiles 3D genome folding at high resolution and over long distances, for all genes and their enhancers, identifying cell-type specific contacts and providing complete genome connectivity to disease pathways for the discovery of novel targets and biomarkers. 3D genomics can identify novel disease genes, reveal mechanisms of drug action, stratify patients and more.
Enhanc3D is using this approach to identify the right target, in the right cell for the right patient, enabling its commercial and academic partners to both optimally arm and de-risk their drug discovery process.
Dr Jones said: “My time as COO and interim CEO has been highly rewarding, and I am now honoured and excited to have been appointed to continue to lead Enhanced Genomics as CEO. I am grateful for the trust placed in me by the Board and look forward to continuing to lead the company through our pivotal transition period to full commercialisation of our 3D genomics platform.”